NCT04186208 (JUNOVO) is a clinical trial of NOVOCART 3D in Cartilage Disease, sponsored by Tetec AG.

Who is sponsoring NCT04186208?

NCT04186208 is sponsored by Tetec AG.

What drugs are being tested in NCT04186208?

Interventions in NCT04186208: NOVOCART 3D.

What condition does NCT04186208 study?

NCT04186208 studies Cartilage Disease.

Is NCT04186208 still recruiting?

NCT04186208 is currently active, enrolled. Last updated 9 May 2025.

Last reviewed 2025-05-09 · How we verify

NCT04186208: JUNOVO

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Prospective, Non-interventional Study to Evaluate the Efficacy and Safety of NOVOCART® 3D for the Treatment of Cartilage Defects of the Knee in Pediatric Patients With Closed Epiphyses

Active, enrolled Last updated 9 May 2025

What this trial tests

trial testing NOVOCART 3D in Cartilage Disease in 42 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

25 April 2017

Primary endpoint
14 June 2023

1 June 2026

Quick facts

Lead sponsor	Tetec AG
Status	Active, enrolled
Study type	OBSERVATIONAL
Enrollment	42
Start date	25 April 2017
Primary completion	14 June 2023
Estimated completion	1 June 2026
Sites	6 locations across Germany

Drugs / interventions tested

NOVOCART 3D — full drug profile →

Conditions studied

Cartilage Disease — all drugs for Cartilage Disease →

Sponsor

Tetec AG — full company profile →

Who can join

Adults 13 to 17, any sex, with Cartilage Disease. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Change of Overall KOOS (Knee Injury and Osteoarthritis Outcome Score)
Time frame: 24 months Follow Up (FU)
Change of KOOS defined as the average of the 5 subscale scores (range 0-100, higher values represent a better outcome)

Sponsor's own description

Prospective, multicenter, single-arm non-interventional study to evaluate the efficacy, safety and health economics of NOVOCART 3D in the Treatment fo cartilage defects of the knee in pediatric patients wieh closed epiphyseal growth plates.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Advanced Therapy medicinal products for autologous chondrocytes and comparison of regulatory systems in target countries.
Kim J, Park J, Song SY, Kim E. · · 2022 · cited 14× · PMID 35582708 · DOI 10.1016/j.reth.2022.04.004

Verify or expand the search:

Other recruiting trials for Cartilage Disease

Currently open trials in the same condition.

NCT06525545 — Early MOtion Total Ankle Artroplasty · NA · recruiting

Other Tetec AG trials

Trials by the same sponsor.

NCT03808623 — Non-interventional Study With NOVOCART® Basic in Patients Treated for Cartilage Defects in the Knee With MAC · completed
NCT03319797 — NOVOCART® Inject Plus for Cartilage Defects of the Knee · Phase 3 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04186208 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Tetec AG
Last refreshed: 9 May 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04186208.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing